Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China-Reference-Cited by-同舟云学术

Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China

Published:2023-04-24 Issue:6 Volume:23 Page:683-690
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Zheng Zhiwei¹,Fang Ling¹,Cai Hongfu²,Zhu Huide¹

Affiliation:

1. Department of pharmacy, Cancer hospital of Shantou University Medical College, Shantou, China

2. Department of pharmacy, Fujian Medical University Union Hospital, Fujian Medical University, Fuzhou, China

Funder

Shantou Science and Technology Project

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2206570

Reference38 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

3. International trends in esophageal cancer incidence rates by histological subtype (1990–2012) and prediction of the rates to 2030

4. A Recurrence Predictive Model for Node-negative Esophageal Squamous Cell Carcinoma After Upfront Esophagectomy

5. Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma;Scientific Reports;2024-07-31

2. Sugemalimab combined with chemotherapy for the treatment of advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis;Frontiers in Pharmacology;2024-06-28

3. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China;PLOS ONE;2024-05-15

4. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis;Expert Review of Pharmacoeconomics & Outcomes Research;2023-11-30

5. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China;Expert Review of Pharmacoeconomics & Outcomes Research;2023-10-24